Your browser doesn't support javascript.
loading
Bone and Joint Tissue Penetration of the Staphylococcus-Selective Antibiotic Afabicin in Patients Undergoing Elective Hip Replacement Surgery.
Menetrey, Annick; Janin, Annick; Pullman, John; Overcash, J Scott; Haouala, Amina; Leylavergne, François; Turbe, Laurent; Wittke, Frederick; Nicolas-Métral, Valérie.
Afiliação
  • Menetrey A; Debiopharm International SA, Lausanne, Switzerland annick.menetrey@debiopharm.com.
  • Janin A; Debiopharm International SA, Lausanne, Switzerland.
  • Pullman J; St. James Healthcare, SCL Health, Butte, Montana, USA.
  • Overcash JS; Sharp Grossmont Hospital, La Mesa, California, USA.
  • Haouala A; Debiopharm International SA, Lausanne, Switzerland.
  • Leylavergne F; Debiopharm International SA, Lausanne, Switzerland.
  • Turbe L; Atlanbio, Saint-Nazaire, France.
  • Wittke F; Debiopharm International SA, Lausanne, Switzerland.
  • Nicolas-Métral V; Debiopharm International SA, Lausanne, Switzerland.
Article em En | MEDLINE | ID: mdl-30559136
ABSTRACT
Afabicin (formerly Debio 1450, AFN-1720) is a prodrug of afabicin desphosphono (Debio 1452, AFN-1252), a novel antibiotic in development which targets the staphylococcal enoyl-acyl carrier protein reductase (FabI) and exhibits selective potent antibacterial activity against staphylococcal species, including methicillin-resistant Staphylococcus aureus As part of clinical development in bone and joint infections, a distribution study in bone was performed in 17 patients who underwent elective hip replacement surgery. Patients received 3 doses of 240 mg afabicin orally (every 12 h) at various time points before surgery. Afabicin desphosphono concentrations were measured by liquid chromatography-tandem mass spectrometry in plasma, cortical bone, cancellous bone, bone marrow, soft tissue, and synovial fluid collected during surgery at 2, 4, 6, or 12 h after the third afabicin dose. The study showed good penetration of afabicin desphosphono into bone tissues, with mean area under the curve ratios for cortical bone-, cancellous bone-, bone marrow-, soft tissue-, and synovial fluid-to-total plasma concentrations of 0.21, 0.40, 0.32, 0.35, and 0.61, respectively. When accounting for the free fraction in plasma (2%) and synovial fluid (9.4%), the mean ratio was 2.88, which is indicative of excellent penetration and which showed that the afabicin desphosphono concentration was beyond the MIC90 of S. aureus over the complete dosing interval. These findings, along with preclinical efficacy data, clinical efficacy data for skin and soft tissue staphylococcal infection, the availability of both intravenous and oral formulations, and potential advantages over broad-spectrum antibiotics for the treatment of staphylococcal bone or joint infections, support the clinical development of afabicin for bone and joint infections. (This study has been registered at ClinicalTrials.gov under identifier NCT02726438.).
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Infecções Estafilocócicas / Benzofuranos / Infecções Relacionadas à Prótese / Staphylococcus aureus Resistente à Meticilina / Antibacterianos / Naftiridinas Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Revista: Antimicrob Agents Chemother Ano de publicação: 2019 Tipo de documento: Article País de afiliação: Suíça

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Infecções Estafilocócicas / Benzofuranos / Infecções Relacionadas à Prótese / Staphylococcus aureus Resistente à Meticilina / Antibacterianos / Naftiridinas Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Revista: Antimicrob Agents Chemother Ano de publicação: 2019 Tipo de documento: Article País de afiliação: Suíça